Advanced search: Search from
Select basic information for advanced search
| Free word |
|---|
| Details |  |
|---|---|
| Related links |  |
| Search |  |
Rchr
J-GLOBAL ID：201801001183144086
Update date: Feb. 27, 2025 Yoshino Takayuki
ヨシノ タカユキ | Yoshino Takayuki
Clips
-
About -
Other affiliations (1)：
Papers (328)：
- Hideaki Bando, Shogo Kumagai, Daisuke Kotani, Saori Mishima, Takuma Irie, Kota Itahashi, Yosuke Tanaka, Takumi Habu, Sayuri Fukaya, Masaki Kondo, et al. Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma - a multicenter phase 2 trial (EPOC1802). Nature cancer. 2025
- Shin Kobayashi, Yoshiaki Nakamura, Tadayoshi Hashimoto, Hideaki Bando, Eiji Oki, Takahiro Karasaki, Hidehito Horinouchi, Yukinori Ozaki, Hiroji Iwata, Taigo Kato, et al. Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing. International journal of clinical oncology. 2025
- Hideaki Bando, Yoichi Naito, Tomoyuki Yamada, Takao Fujisawa, Mitsuho Imai, Yasutoshi Sakamoto, Yusuke Saigusa, Kouji Yamamoto, Yutaka Tomioka, Nobuyoshi Takeshita, et al. A prospective study comparing highly qualified Molecular Tumor Boards with AI-powered software as a medical device. International journal of clinical oncology. 2025. 30. 2. 172-179
- John H Strickler, Tanios Bekaii-Saab, Andrea Cercek, Volker Heinemann, Yoshiaki Nakamura, Kanwal Raghav, Salvatore Siena, Josep Tabernero, Eric Van Cutsem, Takayuki Yoshino, et al. MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer. Future oncology (London, England). 2025. 21. 3. 303-311
- Mitsuho Imai, Yoshiaki Nakamura, Takayuki Yoshino. Transforming cancer screening: the potential of multi-cancer early detection (MCED) technologies. International journal of clinical oncology. 2025. 30. 2. 180-193
- Kentaro Yamazaki, Satoshi Yuki, Hiroya Taniguchi, Hideaki Bando, Yu Sunakawa, Manabu Shiozawa, Hisateru Yasui, Naoki Takahashi, Hironaga Satake, Nobuhisa Matsuhashi, et al. Impact of plasma VEGF-A, VEGF-D and PlGF on the efficacy of 2nd-line chemotherapy combined with biologics in mCRC. ANNALS OF ONCOLOGY. 2022. 33. S479-S479
- 三島 沙織, 吉野 孝之. 【MSI-H Cancerの診断と治療】 大腸がんにおけるMSI Status. 癌と化学療法. 2018. 45. 11. 1567-1572
- 賀川 義規, 加藤 健志, 坂東 英明, 赤木 究, 傳田 忠道, 仁科 智裕, 小松 嘉人, 沖 英次, 工藤 敏啓, 山中 竹春, et al. A multicentre,prospective clinical evaluation study for analyzing RAS mutational status utilizing plasma circulating tumor DNA in patients with metastatic colorectal cancerの解説. 腫瘍内科. 2018. 22. 5. 566-570
- 傳田 忠道, 設楽 紘平, 山中 竹春, 辻 靖, 篠崎 勝則, 小松 嘉人, 小林 良充, 古瀬 純司, 加藤 健志, 大橋 靖雄, et al. REVERCE:大腸癌のRegorafenib-Cetuximab逐次投与ランダム化第II相試験(biomarker解析). 日本癌治療学会学術集会抄録集. 2018. 56回. O48-1
- 谷口 浩也, 吉野 孝之. 【がんのPrecision Medicine(精密医療)-SCRUM-Japanの取り組みを中心に-】 消化器がん遺伝子スクリーニングネットワーク(GI-SCREEN-Japan)の活動と展望. Progress in Medicine. 2018. 38. 9. 983-986
- PhD (Kagawa University)
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.
Return to Previous Page
